Vivos Therapeutics Inc (VVOS) - Total Assets
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) holds total assets worth $25.04 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Vivos Therapeutics Inc (VVOS) balance sheet quality index to measure how much of total assets are equity-financed.
Vivos Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check VVOS goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Vivos Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vivos Therapeutics Inc's total assets of $25.04 Million consist of 17.4% current assets and 82.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $1.58 Million | 6.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.04 Million | 16.1% |
| Goodwill | $8.57 Million | 34.1% |
Asset Composition Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VVOS stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vivos Therapeutics Inc's current assets represent 17.4% of total assets in 2025, a decrease from 24.5% in 2018.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 15.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, a decrease from 58.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 34.1% of total assets.
Vivos Therapeutics Inc Competitors by Total Assets
Key competitors of Vivos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Vivos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.27 | 0.77 | 4.23 |
| Quick Ratio | 0.27 | 0.77 | 4.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-13.12 Million | $-1.09 Million | $30.07 Million |
Vivos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Vivos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.86 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 64.6% |
| Total Assets | $25.15 Million |
| Market Capitalization | $7.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vivos Therapeutics Inc's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Vivos Therapeutics Inc's assets grew by 64.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Vivos Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $25.15 Million | +64.56% |
| 2024-12-31 | $15.28 Million | +42.44% |
| 2023-12-31 | $10.73 Million | -21.79% |
| 2022-12-31 | $13.72 Million | -59.27% |
| 2021-12-31 | $33.69 Million | +33.01% |
| 2020-12-31 | $25.33 Million | +235.39% |
| 2019-12-31 | $7.55 Million | -7.95% |
| 2018-12-31 | $8.20 Million | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more